123I-mIBG (meta-iodobenzylguanidine)

DRUG3 trials

Sponsors

GE Healthcare

Conditions

Heart Failure, CongestiveNeuroblastomaPheochromocytoma

Phase 3

Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease

CompletedNCT00126425

GE HealthcareHeart Failure, Congestive

Start: 2005-07-31End: 2008-12-31Updated: 2016-12-13

Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease

CompletedNCT00126438

GE HealthcareHeart Failure, Congestive

Start: 2005-07-31End: 2008-09-30Updated: 2018-03-14

Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma

CompletedNCT00126412

GE HealthcareNeuroblastoma, Pheochromocytoma

Start: 2005-08-02End: 2006-09-27Updated: 2019-05-31

Related Papers

Predicting Risk Versus Predicting Potential Survival Benefit Using <sup>123</sup> I- <i>m</i> IBG Imaging in Patients With Systolic Dysfunction Eligible for Implantable Cardiac Defibrillator Implantation

Circulation Cardiovascular Imaging2015-12-0126 citations

Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study.

2010-02-25569 citations